Fig. 2
Alzheimer’s disease and neurodegeneration biomarker levels among resilient, non-resilient, and 80 + impaired participants. All results were derived from an 2 × 3 (APOE genotype x cognitive status group) ANCOVA adjusted for baseline age, recruitment region, HT treatment (HT vs. Placebo), education, kidney function (eGFR), diabetes, and high cholesterol. Full results of these analyses are presented in the Supplementary Tables. Results derived from post-hoc comparison of the non-resilient and 80 + impaired groups to the resilient (reference) group
t Interaction between APOE genotype and resilient versus 80 + imparted was statistically significant for plasma Aß42/40 level (interaction-P = 0.03). *Difference between group and resilient group significant at P < 0.05